Advanced Biomedical Technologies FCF Margin
The Free Cash Flow Margin of Advanced Biomedical Technologies (ABMT) as of Jul 23, 2026 is 498.38 %. In the previous year, Free Cash Flow Margin was -6,505.13 % — a change of -107.66% (higher).
Get this data via API
Financial Data API
FCF Margin
498.38 %
YoY
-107.66%
Last updated:
Free Cash Flow Margin of Advanced Biomedical Technologies is 2026 498.38 % . Free Cash Flow Margin of Advanced Biomedical Technologies was 2025 -6,505.13 % . It decreases by -107.66% higher compared to the previous year.
Access this data via the Eulerpool API
Advanced Biomedical Technologies Stock analysis
What does Advanced Biomedical Technologies do? Advanced Biomedical Technologies Inc is an innovative biomedical company specializing in the development of advanced medical devices and technologies. The company was founded in 1985 by an experienced team of biotech experts and is headquartered in California, USA.
History:
The company's roots lie in the research and development of novel medical implants and prosthetics. However, over the years, the company has quickly evolved into a leading provider of medical devices and technologies in the fields of diagnostics, therapy, and care.
Business model:
The business model of Advanced Biomedical Technologies Inc is focused on providing innovative and advanced solutions for medical care. The company strives to continuously develop its products and help customers achieve their healthcare goals.
Divisions:
The company is divided into four main divisions focusing on different medical areas:
1) Interventional Cardiology: Here, the company develops devices for the treatment of heart diseases, such as stents for reopening narrowed vessels.
2) Orthopedics: Another focus is on the development of innovative orthopedic implants and prosthetics that help patients regain their mobility and improve their quality of life.
3) Oncology: In this division, the company works on the development of medical devices and systems for the diagnosis and treatment of cancer.
4) Neurology: Here, the company focuses on the development of medical technologies and devices for the diagnosis and treatment of nervous system disorders, such as Parkinson's or Alzheimer's.
Products:
Advanced Biomedical Technologies Inc's products include a variety of medical devices and technologies specialized in different medical areas. Some of the company's most well-known products are:
- Stents for reopening narrowed vessels in the heart
- Artificial joints and implants for restoring mobility and quality of life
- Medical devices for the diagnosis and treatment of cancer
- Neurostimulation devices for the treatment of chronic pain and other neurological disorders
- Robot-assisted surgery systems that assist surgeons in complex procedures.
Conclusion:
Advanced Biomedical Technologies Inc is a leading biomedical company specializing in the development of advanced medical devices and technologies. The company has a long history in the research and development of medical implants and prosthetics but has quickly expanded into a broader range of medical applications. With its focus on developing innovative products for patients' quality of life, Advanced Biomedical Technologies Inc will continue to play an important role in medical innovation. Advanced Biomedical Technologies is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Advanced Biomedical Technologies stock
Free Cash Flow Margin of Advanced Biomedical Technologies is 498.38 % in 2026.
Access this data via the Eulerpool API
Margins — Advanced Biomedical Technologies
All Key Metrics — Advanced Biomedical Technologies
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth